Can-Fite BioPharma Ltd. (CANF) Form 6-K — Jul 6, 2026
Can-Fite BioPharma announced the completion of enrollment for the interim analysis of its pivotal Phase 3 study evaluating Piclidenoson for moderate-to-severe plaque psoriasis. The study has enrolled the first 247 patients required for this pre-specified analysis under a protocol agreed upon with both the FDA and EMA. The interim analysis will evaluate efficacy and safety data, with results expected during the fourth quarter of 2026 or the first quarter of 2027. The trial is a randomized, double-blind, placebo-controlled study using 3 mg Piclidenoson tablets administered orally twice daily.
Key figures
- Dose
- 3 mg
- Endpoint Week
- 16
- Patients Enrolled
- 247
- Interim Analysis Timeline
- Q4 2026/Q1 2027
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.